Skip to content
Agentic OS
Menu

Intelligence / Healthtech / PMA Approvals / Boston Scientific Corp

Approvalsdevice change approved (PMA)9 Sept 2026

Boston Scientific Corp

9 Sept 2026: Device change approved (PMA) · WaveWriter Alpha™ and WaveWriter Alpha™ Prime SCS Systems; Celestia and Celestia Prime SCS Systems. Recorded in the openFDA device PMA data.

View the source record

Decided
9 Sept 2026
Device
WaveWriter Alpha™ and WaveWriter Alpha™ Prime SCS Systems; Celestia and Celestia Prime SCS Systems
Specialty
Neurology
Type
Supplement (Normal 180 Day Track)
Reason
Labeling Change - Indications/instructions/shelf life/tradename
Reference
P030017 S396
Location
Valencia, CA
What this signal means

A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.

  1. Cardiovascular leads with 53 of 120, then Pathology (15).
  2. 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Boston Scientific Corp

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Boston Scientific Corp in our registers.

More in Neurology

PMA Approvals

See all

Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.